Daxxify. The longer-lasting neurotoxin.

Most neurotoxins are stabilized with human serum albumin, a blood-derived protein. Daxxify replaces it with a small synthetic peptide that binds the active molecule and — per the manufacturer's account — helps it stay where it's placed and persist longer at the nerve ending. It's the first neurotoxin formulated without human- or animal-derived components.

The duration data comes from the product's pivotal trials, where the median time before patients returned to baseline ran roughly six months, with a meaningful share holding effect toward nine. The honest framing: those are trial figures. In day-to-day practice we see many Daxxify patients comfortably reach five to six months — clearly longer than conventional products, if not always the trial ceiling. Onset can run slightly slower than Botox for some patients, and the wear-off, when it comes, is just as gradual.

Patients on conventional neurotoxins visit three to four times a year. Daxxify's pitch is two. That matters most for people whose calendar is the constraint: frequent travelers, patients who book months out, anyone who keeps arriving at appointments having fully worn off — which means starting over rather than maintaining.

It's not for everyone. First-time patients are usually better served by a shorter-acting product for the opening round: if the dose or placement needs adjusting, you want that lesson to last four months, not nine. Patients who like to fine-tune season by season feel the same way. We'll often run a conventional product first and graduate a patient to Daxxify once the pattern is dialed in.

Per treatment, Daxxify carries a premium — at Los Angeles market rates an upper-face treatment typically runs $550 – $850, against $400 – $700 for the same areas with a conventional product. Looked at per visit, that reads as the expensive option.

Per year, the math tightens. Two Daxxify treatments versus three or four conventional ones lands the annual figure in a comparable band, and sometimes under it — before counting the appointments you didn't have to book. Whether the premium is worth it is mostly a question about your tolerance for visits, not your budget. Exact totals are discussed at consultation, in writing, like everything else we price.

Daxxify earned FDA approval in 2022. Its trial program was large and its safety profile so far looks consistent with the category — but Botox has decades of accumulated use behind it, and there's no pretending those track records are equivalent yet. Some patients reasonably prefer the product with the longest history; some prefer Dysport's fast onset or Xeomin's stripped-down formulation. All are sound choices.

Our role isn't to sell the newest thing. It's to lay out the four products we stock — what each does well, what it costs over a year, what we'd choose in your position — and let the decision be yours. That conversation is what the consultation is for.